Treatment of diffuse subretinal fibrosis uveitis with rituximab. Issue 2 (30th May 2014)

• Record Type: Journal Article
• Authors: Spiteri Cornish, Kurt; Kuffova, Lucia; Forrester, John V
• Is Part Of: British journal of ophthalmology. Volume 99:Issue 2(2015)
• Page Start: 153
• Page End: 154
• Publication Date: 2014-05-30
• Subjects: Immunology -- Inflammation -- Retina; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjophthalmol-2013-304686
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Diffuse subretinal fibrosis uveitis (DUS) syndrome is a rare form of granulomatous multifocal choroiditis (MFC) characterised by enlarging areas of subretinal fibrosis (SRF) which coalesce with subsequent macular involvement and visual loss. First described by Palestine, DUS carries a poor visual prognosis despite use of high-dose corticosteroids and systemic immunosuppression. We report two cases of bilateral DUS successfully treated with rituximab. We believe given the B-cell predominance in the underlying pathogenesis of the disease, rituximab should be considered first line in the management of this potentially devastating disease.